Case Report Medical Physics Nephrology
Vitamin D supplementation and time to diagnosis in preterm neonates: A case series

Vitamin D supplementation and time to diagnosis in preterm neonates: A case series

Authors

Adam Kim

Adam Kim

Charité Berlin, Cape Verde

Corresponding
Yusuf Larsen

Yusuf Larsen

American University of Beirut Medical Center, Guyana

Published

September 25, 2026

Paper ID

PAP-000231

Status

Published

DOI

10.65712/tmj.test000489

Vitamin D supplementation and time to diagnosis in preterm neonates: A case series

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: The cost of time to diagnosis to health systems is substantial. Methods: We conducted a case series across 1 centres between 2018 and 2022. Results: Serious adverse events were rare and similar between groups. 484 participants were included (median age 78 years). Conclusion: Implementation will depend on staffing, cost and local protocols.

Introduction

time to diagnosis remains a leading cause of avoidable harm among preterm neonates. Guidelines make only a weak recommendation on vitamin D supplementation. The cost of time to diagnosis to health systems is substantial.

Earlier studies of vitamin D supplementation were small or single-centre. Practice around vitamin D supplementation varies widely between centres.

The cost of time to diagnosis to health systems is substantial. Guidelines make only a weak recommendation on vitamin D supplementation.

Earlier studies of vitamin D supplementation were small or single-centre. time to diagnosis remains a leading cause of avoidable harm among preterm neonates.

Discussion

Strengths include the sample size and blinded outcome assessment. Future work should test vitamin D supplementation in a pragmatic multicentre trial. These findings suggest that vitamin D supplementation is associated with better time to diagnosis in preterm neonates.

These findings suggest that vitamin D supplementation is associated with better time to diagnosis in preterm neonates. Residual confounding cannot be excluded.

Conclusions

Vitamin D supplementation merits wider use for preterm neonates to improve time to diagnosis.

References

1. Novak M, Dubois E, et al. Delayed cord clamping and ventilator-free days. N Engl J Med. 2018;252(6):469-1006.

2. Schmidt N, Okafor O, et al. Continuous glucose monitoring and length of stay. BMC Med. 2015;164(5):605-1132.

3. Novak F, Volkov O, et al. Tranexamic acid and post-operative delirium. Diabetes Care. 2025;310(6):822-1331.

4. Nasser R, Lindqvist H, et al. High-flow nasal oxygen and ventilator-free days. Crit Care Med. 2008;240(4):645-1441.

5. Okafor R, Yilmaz H, et al. An antibiotic stewardship programme and 30-day readmission. BMC Med. 2008;208(7):42-1594.

6. Okafor W, Patel F, et al. Nurse-led discharge planning and medication adherence. Ann Intern Med. 2009;230(2):481-1352.

Appendices

Supplementary tables are available on request.

Materials and Methods

Analyses were adjusted for age, sex and baseline severity. Eligible participants were preterm neonates.

Analyses were adjusted for age, sex and baseline severity. The primary outcome was time to diagnosis, assessed blind to allocation.

We conducted a case series across 4 centres between 2017 and 2025. Missing data were handled with multiple imputation.

Results

Serious adverse events were rare and similar between groups. time to diagnosis occurred in 15% of the intervention group versus 14% of controls. The adjusted odds ratio was 0.68 (95% CI 0.30 to 0.61).

time to diagnosis occurred in 14% of the intervention group versus 29% of controls. time to diagnosis occurred in 15% of the intervention group versus 36% of controls. Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.89 (95% CI 0.50 to 0.87). The adjusted odds ratio was 0.49 (95% CI 0.26 to 0.65). time to diagnosis occurred in 8% of the intervention group versus 20% of controls.

GroupnEventsRate %OR
Age ≥ 652337513.10.50
Control4128418.80.48
Age ≥ 657543518.00.62
Male7727116.70.86
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in time to diagnosis
Shown for preterm neonates; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. time to diagnosis occurred in 19% of the intervention group versus 38% of controls. Serious adverse events were rare and similar between groups.